UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 13, 2023

EyePoint Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware	**000-51122**	**26-2774444**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

480 Pleasant Street	
Watertown, Massachusetts	**02472**
(Address of Principal Executive Offices)	**(Zip Code)**

Registrant's Telephone Number, Including Area Code: (617) 926-5000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, par value $0.001	EYPT	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On September 13, 2023, EyePoint Pharmaceuticals, Inc. posted an updated investor presentation on its website at www.eyepointpharma.com. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Investor Presentation of EyePoint Pharmaceuticals, Inc. dated September 13, 2023
104	Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EYEPOINT PHARMACEUTICALS, INC.

Date: September 13, 2023

By: /s/ George O. Elston
George O. Elston
Chief Financial Officer

Exhibit 99.1

EYEPOINT® PHARMACEUTICALS

Investor Presentation

September 2023

Forward-Looking Statements

Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about the sufficiency of our existing cash resources into 2025; our expectations regarding the timing and clinical development of our product candidates, including EYP-1901; the potential for EYP-1901 as a novel sustained delivery treatment for serious eye diseases, including wet age-related macular degeneration, non-proliferative diabetic retinopathy and diabetic macular edema; our potential to receive future payments from Alimera pursuant to our May 2023 sale and license agreement with Alimera; and our longer term financial and business goals and expectations, are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; our ability to access needed capital; our ability to successfully manufacture sufficient quantities of YUTIQ® pursuant to our supply agreements with Alimera and Ocumension Therapeutics; the success of current and future license agreements, including our agreements with Alimera, Ocumension Therapeutics, Equinox Science and Betta Pharmaceuticals; termination or breach of current and future license agreements; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of guidelines, recommendations and studies; protection of our intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of our stock price; possible dilution; absence of dividends; the extent to which COVID-19 impacts our business and the medical community; the impact of instability in general business and economic conditions, including changes in inflation, interest rates and the labor market; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

COMPANY OVERVIEW

Committed to developing therapeutics to improve the lives of patients with serious retinal disease

Pipeline represents multi billion-dollar opportunities

- **EYP-1901** –bioerodible intravitreal (IVT) insert of patented vorolanib tyrosine kinase inhibitor (TKI) for retinal disease
  - Topline Phase 2 data in **wet AMD** anticipated in Dec 2023
  - Topline Phase 2 data in **NPDR** anticipated in 2Q 2024
  - Phase 2 trial in **DME** planned for Q1 2024

Durasert® - proven IVT drug delivery technology

- Routine in-office IVT injection
- Able to deliver up to 3 inserts per injection
- Safely administered to ~80,000 patient eyes across four FDA approved products with non erodible Durasert

Strong Balance Sheet

- $142.5M of cash and investments on June 30, 2023
- No debt
- Cash runway into 2025

EyePoint Pharmaceuticals

Pipeline Represents Multibillion Dollar Product Opportunities

Program	Indication	Discovery	Pre-Clin	Phase 1	Phase 2	Phase 3	Next Milestone
EYP-1901 – (vorolanib in Durasert E™)	wet AMD	*single dose 6-month maintenance therapy 160 patients fully enrolled*					Topline data in December 2023
	NPDR	*single dose 9-month treatment 77 patients fully enrolled*					Topline data in Q2 2024
	DME	*single dose 6-month treatment*					Trial Initiation in Q1 2024
EYP-2301 - (Tie 2 Activation)	DME wet AMD						Pre-Clinical Tox and PK data in 2024
Complement Inhibition Programs	GA						Potential product candidate in 2024

non-clinical *trial planned* *trial underway*

wet AMD, wet age-related macular degeneration; NPDR, non-proliferative diabetic retinopathy; DME, diabetic macular edema; GA, geographic atrophy

EyePoint Pharmaceuticals

TECHNOLOGY

DURASERT®

Safe Sustained IVT Drug Delivery

Used in four of six FDA approved intravitreal sustained delivery products

Delivered by a single in-office IVT injection

Continuous, stable release of drug with zero-order kinetics

Durasert E™: bioerodible

- Polyimide coating removed
- Bioerodible matrix
- Designed to deplete drug load before fully eroding

Durasert®: non-erodible

- YUTIQ® (Alimera)
- ILUVIEN® (Alimera)
- RETISERT® (B&L)
- VITRASERT® (B&L)

EyePoint PHARMACEUTICALS

EYP-1901 Delivers VEGF Receptor Binding Vorolanib Using Durasert E™



- A single IVT injection
- New MOA in potential treatment of VEGF mediated retinal diseases
- Positioned to be complementary to approved anti-VEGF therapies
- Sustained delivery of drug between ~8-9 months
- Positive safety and efficacy results in wet AMD from Phase 1 DAVIO clinical trial

EyePoint Pharmaceuticals

WHY VOROLANIB?

Vorolanib is a selective pan-VEGF receptor blocker

- Composition of matter patent into 2037
- Previous Phase 1 and Phase 2 clinical trials in wet AMD as an oral therapy showed compelling efficacy data with no ocular toxicity observed[1,2]
- In-vivo studies demonstrate encouraging neuroprotection data and potential anti-fibrosis effect[3]
- Reduced off-target binding of receptors associated with systemic side effects of kinase inhibitors (TKIs)

1. Jackson et al. JAMA Ophthalmol 2017
2. 2. Cohen MN et al. Br J Ophthalmol. 2021
3. ARVO 2023 presentation

EyePoint Pharmaceuticals

Vorolanib Binds Receptors of All VEGF Growth Factors With Strong Affinity To VEGF Receptor 2 - A Receptor Associated With Blood Vessel Leakage

- Vorolanib inhibits pathways with key roles in **angiogenesis** and **pathological vascular leakage**
  - Potent and selective **pan–VEGF receptor** inhibitor
  - Does not inhibit **TIE2** receptors at clinically relevant doses
- Acts **intracellularly** and inhibits proangiogenic signaling



ANG, angiopoietin; PDGF(R), platelet-derived growth factor (receptor); PLGF, placental growth factor; TIE2,tyrosine-protein kinase receptor TIE-2; VEGF(R), vascular endothelial growth factor (receptor).

EyePoint Pharmaceuticals

Vorolanib Demonstrated The Ability To Provide Retinal Neuroprotection In Validated Mouse Model

Mean Change in Contrast Vision at Day 16 from Baseline in Animals Treated with Vorolanib vs Vehicle Control



34% reduction in loss of contrast vision vs. control

Retinal thickness measured by vertical and horizontal OCT scans



<1% Overall loss of ONL vs control

Data presented at ARVO 2023 ONL: Outer Nuclear Layer

EyePoint Pharmaceuticals

EYP-1901

PHASE 1 DAVIO CLINICAL TRIAL RESULTS IN WET AMD

EyePoint Pharmaceuticals

EYP-1901 Phase 1 DAVIO Clinical Trial Met All Objectives

FAVORABLE SAFETY PROFILE

- No ocular SAEs reported
- No drug-related systemic SAEs reported
- Ocular AEs – majority are mild and expected

POSITIVE EFFICACY & DURABILITY

- Stabilization of mean BCVA and OCT throughout 6 months was achieved
- 53% up to 6-months with no anti-VEGF supplemental injection
- 75% reduction in treatment burden at 6-months



SIX MONTHS MEDIAN TIME
TO SUPPLEMENTAL ANTI-VEGF INJECTION

EYP-1901

Phase 1 DAVIO clinical trial demonstrated a favorable safety profile, meeting the primary safety endpoint

Favorable safety profile

- No ocular serious adverse events (SAEs)
- No drug related systemic SAEs
- No drug related ocular or systemic toxicity
- No Durasert related toxicity or tolerance issues
- No dose limiting toxicity

No ocular AEs of key interest observed

- No vitreous floaters, endophthalmitis, retinal detachment, implant migration in the anterior chamber, retinal vasculitis, posterior segment inflammation

Ocular AEs observed:

- One eye: mild asymptomatic anterior chamber cell/flare
- One eye: asymptomatic vitreous hemorrhage from injection observed

EyePoint Pharmaceuticals

BCVA and CST Stable At 6 And 12 Months After Single Treatment Of EYP-1901 In The DAVIO Clinical Trial

Parameter	6 Months	12 Months
BCVA	−2.5	−4.1
CST	−3.4	−2.8





BCVA: best corrected visual acuity

OCT: optical coherence tomography; CST: central subfield thickness

Error bars represent the standard deviation.

EyePoint Pharmaceuticals

EYP-1901 Phase 1 DAVIO Clinical Trial Demonstrated Clinically Significant Reduction In Treatment Burden Of 75% At 6-Months

SOC Anti-VEGF Injections Before and After Treatment



EYP-1901 Phase 1 DAVIO Clinical Trial Maintained A Clinically Significant Reduction In Treatment Burden Of 73% At 12-Months

SOC Anti-VEGF Injections Before and After Treatment



EYEPOINT PHARMACEUTICALS

EYP-1901 Phase 1 DAVIO Clinical Trial Demonstrated That 53% Of Patients Did Not Require Supplemental Anti-VEGF Treatment At 6-Months

Median time to supplemental anti-VEGF: 6 months



EYEPOINT PHARMACEUTICALS

EYP-1901

PHASE 1 DAVIO CLINICAL TRIAL IN WET AMD SUBGROUP ANALYSIS – NINE SUBJECTS WITH NO EXCESS FLUID AT SCREENING

EyePoint Pharmaceuticals

DAVIO Subgroup of Eyes with No Excess Fluid At Screening Showed Stable BCVA and CST At 6-Months

BCVA = -0.4 letters at 6 months

Mean change in BCVA from screening visit



BCVA: best corrected visual acuity

CST on OCT = -1.0 microns at 6 months

Mean change in CST from screening visit

OCT: optical coherence tomography; CST: central subfield thickness

EyePoint Pharmaceuticals

DAVIO Subgroup With No Excess Fluid At Screening Showed Stable BCVA and CST Through 12-Months

BCVA = -0.4 letters at 6 months
+0.7 letters at 11 months
-2.2 letters at 12 months

CST on OCT = -1.0 microns at 6 months
+0.4 microns at 11 months
+10.9 microns at 12 months

Mean change in BCVA from screening visit



Mean change in CST from screening visit



DAVIO 12-month final data

EyePoint Pharmaceuticals

DAVIO Subgroup With No Excess Fluid At Screening Showed A 92% Reduction In Treatment Burden At 6 Months



DAVIO Subgroup With No Excess Fluid At Screening Showed An 89% Reduction In Treatment Burden At 12-Months



DAVIO Subgroup With No Excess fluid At Screening Demonstrated That 67% Did Not Require A Supplemental Anti-VEGF Injection At 6-Months

Median time to supplemental anti-VEGF: 12 months



DAVIO 12-month final data

EyePoint Pharmaceuticals

EYP-1901

TREAT TO MAINTAIN IN WET AMD

EyePoint Pharmaceuticals

DAVIO Clinical Trial Data Supports Advancing EYP-1901 As A Maintenance Treatment For Wet AMD



TREAT TO MAINTAIN WITH EYP-1901

- About half of eyes in DAVIO could go up to 6 months on EYP-1901 alone
- Another ~30% received only a single supplemental anti-VEGF during 6-months
- About 15 % failed both SoC and EYP-1901 and required multiple supplements

EyePoint Pharmaceuticals

EYP-1901 Is Advancing As A Potential Maintenance Therapy In Wet AMD

- ***Treat*** newly diagnosed patients with anti-VEGF of choice to reach desired “dry” outcome
- ***Maintain*** with EYP-1901on six-month intervals providing new MOA and sustained delivery
- ***Supplement*** with current anti-VEGF biologic, if needed

Based on DAVIO Phase 1 outcomes, we believe over half of all wet AMD eyes may be maintained visually and anatomically with EYP-1901 alone

EyePoint Pharmaceuticals

EYP-1901

WET AMD PHASE 2 CLINICAL TRIAL - DAVIO 2

EyePoint Pharmaceuticals

DAVIO 2 CLINICAL TRIAL

The Phase 2 DAVIO 2 clinical trial for EYP-1901 in wet AMD was designed to support initiation of Phase 3 clinical trials in 2024

Phase 2 design includes DAVIO Phase 1 learnings and FDA interaction

- Type C meetings held with FDA
- CST below 350um at screening to eliminate poor responders to standard of care treatment
- Only previously treated wet AMD patients
- **Primary outcome is difference in change in BCVA at Week 28 and 32 (blended)**

EyePoint Pharmaceuticals

EYP-1901 Phase 2 DAVIO 2 Clinical Trial Is Randomized, Double-Masked, Aflibercept Controlled With A Single EYP-1901 Treatment At Two Doses

- REQUIRED AFLIBERCEPT INJECTION VISIT
- VISIT SCHEDULED
- EYP-1901 DOSE

EyePoint Pharmaceuticals

Phase 1 DAVIO and Phase 2 DAVIO 2 Trials Patient Demographics

Phase 1 DAVIO Baseline Characteristics (N = 17)*	
Mean age, y (range)	77.4 (67-94)
Female, %	76%
Mean BCVA, ETDRS letters (range)	69 (38-85)
Mean CST, µm (range)	299 (204-441)

Phase 2 DAVIO 2 Baseline Characteristics (N = 160)**	
Mean age, y (range)	76 (52-93)
Female, %	62%
Mean BCVA, ETDRS letters (range)	74 (41-85)
Mean CST, µm (range)	265 (178-400)

** - DAVIO Final 12-Months Data

** - DAVIO 2 unmonitored data cut as of 01Sept2023

EyePoint Pharmaceuticals

DAVIO 2 Masked Safety Summary As Of September 1, 2023 Data-Cut Off

Key findings:

- No drug-related ocular SAEs
- No drug-related systemic SAEs
- 2 ocular SAEs:
  - Retinal detachment in a study eye detected at week 1 (one week post initial aflibercept injection, prior to EYP-1901 injection)
  - Retinal hemorrhage in a non-study fellow eye

EyePoint Pharmaceuticals

EYP-1901

NON-PROLIFERATIVE DIABETIC RETINOPATHY - PHASE 2 CLINICAL TRIAL (PAVIA)

EyePoint PHARMACEUTICALS

Diabetic Retinopathy Market Opportunity

- Leading cause of blindness
- Current SoC is watchful waiting until vision loss
- Significant opportunity for a 9-month sustained delivery treatment with EYP-1901

Diabetic Retinopathy Market Size Report. 2018-2020 (GrandViewResearch.com), Global Diabetic Retinopathy Market Size Report. Jan. 2022 (MarketDataForecast.com)

Growing Global DR Market



Analysis includes North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

$12.27 billion

is the estimated market size by 2032, a result of diabetes prevalence and the aging population

EyePoint Pharmaceuticals

EYP-1901 Phase 2 PAVIA Clinical Trial Is Randomized Double-Masked, Single Injection With Sham Control As A 9-Month Treatment In NPDR

- Moderate to severe NPDR patients enrolled
- Primary endpoint is ≥**2 step DRSS improvement score at week 36**
- Secondary endpoints:
  - Reduction in vision-threatening complications
  - DME occurrence and/or proliferative disease
  - Retinal ischemia
  - Safety

EyePoint Pharmaceuticals

PAVIA Masked Safety Summary As Of September 1, 2023 Data-Cut Off

Key findings:

- No drug-related ocular SAEs
- No drug-related systemic SAEs
- 2 ocular SAEs, deemed not drug related by investigators:
  - Hemorrhagic posterior vitreous detachment (PVD) in a study eye eight-week after dosing
  - Macular edema leading to vision loss in the non-study fellow eye

EyePoint Pharmaceuticals

BALANCE SHEET

Solid cash position and cash runway into 2025 while funding Phase 2 trials for EYP-1901

Strong Balance Sheet

- $142.5M of cash and investments on June 30, 2023
- All bank debt retired in May 2023
- **Cash runway into 2025**

EyePoint Pharmaceuticals

Continued Execution And Well Funded Through Key EYP-1901 Milestones

	EYP-1901	
✓	DAVIO 1 trial complete	2Q 2022
✓	DAVIO 2 trial initiated	3Q 2022
✓	PAVIA trial initiated	3Q 2022
✓	DAVIO 2 enrollment complete	1Q 2023
✓	PAVIA enrollment complete	2Q 2023
☐	**DAVIO 2 topline data**	**December 2023**
☐	**DME Trial initiation**	**1Q 2024**
☐	**PAVIA topline data**	**2Q 2024**

	Corporate	
✓	RallyBio complement inhibitor (C5) collaboration	1Q 2023
✓	YUTIQ transacted for $82.5M plus royalties	2Q 2023
✓	Debt retired and cash runway extended into 2025	2Q 2023

EyePoint Pharmaceuticals

EYEPOINT® PHARMACEUTICALS

Investor Presentation

September 2023